Genmab Drug Pipeline

Genmab conducts clinical development across a substantial portfolio of investigational therapies. The company currently has 31 active trials, part of a broader history of 53 registered trials since 2008. Clinical activity spans early- and late-stage development, with 14 programs in Phase 1, 15 in Phase 2, and 10 in Phase 3. Genmab's portfolio is heavily concentrated in oncology, which accounts for all active trials. Within oncology, Non-Hodgkin Lymphoma represents the largest focus with 15 active trials, including 6 in Phase 3. The company also has active programs targeting Solid Tumor (Advanced) (7 active, 0 Ph3), Non-Small Cell Lung Cancer (5 active, 1 Ph3), Ovarian Cancer (3 active, 2 Ph3), and Endometrial Cancer (2 active, 1 Ph3). The weighting toward Phase 3 trials in Non-Hodgkin Lymphoma and Ovarian Cancer suggests a potential for near-term clinical catalysts within the portfolio.